Stoke Therapeutics Inc. reported revenue of $183.0 million for the nine months ended September 30, 2025, up from $13.9 million for the same period in 2024. The increase was primarily due to $150.8 million related to the IP license performance obligation, $11.5 million for global development activities under the Biogen Agreement, and $6.8 million related to the Acadia Agreement. Net income for the nine-month period was $51.0 million, or $0.85 per diluted share, compared to a net loss of $78.5 million, or $1.48 per share, in 2024. Research and development expenses rose to $96.2 million from $65.7 million, and sales, general and administrative expenses for the third quarter increased to $45.9 million from $36.0 million, driven by personnel and launch readiness expenses. As of September 30, 2025, the company held $328.6 million in cash, cash equivalents, and marketable securities, expected to fund operations through mid-2028. Patient recruitment for the Phase 3 EMPEROR study of zorevunersen is ongoing in the U.S., UK, and Japan, with enrollment expected to complete in the second half of 2026.